Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,745
Change Today +30.00 / 1.75%
Volume 40.0M
KLBF On Other Exchanges
Symbol
Exchange
Munich
OTC US
OTC US
As of 5:14 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma tbk pt (KLBF) Snapshot

Open
$1,715
Previous Close
$1,715
Day High
$1,745
Day Low
$1,710
52 Week High
04/23/15 - $1,915
52 Week Low
08/7/14 - $1,580
Market Cap
81.8T
Average Volume 10 Days
29.6M
EPS TTM
$45.27
Shares Outstanding
46.9B
EX-Date
05/26/15
P/E TM
38.5x
Dividend
$19.00
Dividend Yield
1.09%
Current Stock Chart for KALBE FARMA TBK PT (KLBF)

Related News

No related news articles were found.

kalbe farma tbk pt (KLBF) Related Businessweek News

No Related Businessweek News Found

kalbe farma tbk pt (KLBF) Details

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs, energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company provides health facilities consisting of clinics, pharmacies, and mini markets, as well as hemodialisis treatments; contract services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; distributes consumer products, medical equipment, cosmetics, and other trading products; markets and distributes opthalmic products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. The company was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,084 Employees
Last Reported Date: 03/30/15
Founded in 1966

kalbe farma tbk pt (KLBF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma tbk pt (KLBF) Key Developments

PT. Kalbe Farma Tbk. to Report Q2, 2015 Results on Jul 31, 2015

PT. Kalbe Farma Tbk. announced that they will report Q2, 2015 results on Jul 31, 2015

Kalbe Farma Revised Sales Guidance for the Year 2015

Kalbe Farma (Indonesia) revised sales outlook for the year 2015. For the period, the company cut its sales growth target to 7% from 11% year on year. The company also adjusted its annual revenue target to IDR 19 trillion (USD 1.42 billion). Initially the company expects full-year net sales growth of 11% to 13%.

Kalbe Farma Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for 2015

Kalbe Farma announced earnings results for the first quarter of 2015. The company reported a 4.4% rise year on year in first-quarter net sales to IDR 4.2 trillion. For the first quarter of 2015, the company posted a 6.3% year on year rise in operating profit and a 7.2% increase in net profit to IDR 529 billion, mainly due to a wider gross profit margin (49.5% versus 47.8% a year earlier). For 2015, the company forecast full-year net sales growth of 11% to 13% year on year, net earnings growth of 14% to 16% year on year, and an operating profit margin of 16% to 17% year on year. It now forecasts full-year targets of 7% to 9% net sales growth and net earnings growth of 9% to 11% year on year. To company has budgeted IDR 0.9 trillion to IDR 1.1 trillion for capital expenditure aimed at expanding production and distribution capacity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KLBF:IJ 1,745.00 +30.00

KLBF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KLBF.
View Industry Companies
 

Industry Analysis

KLBF

Industry Average

Valuation KLBF Industry Range
Price/Earnings 37.6x
Price/Sales 4.5x
Price/Book 8.0x
Price/Cash Flow 37.6x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA TBK PT, please visit www.kalbe.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.